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BACKGROUND: Although multidrug resistance protein 2 (MRP2) confers chemoresistance in some cancer types, its implication on
oesophageal squamous cell carcinoma (ESCC) remains unclear.
METHODS: We evaluated MRP2 expression by immunohistochemistry and RT–PCR using 81 resected specimens from ESCC patients
who did or did not receive neo-adjuvant chemotherapy (NACT), including 5-fluorouracil, doxorubicin, and cisplatin (CDDP).
Correlation between MRP2 expression and response to chemotherapy was also examined in 42 pre-therapeutic biopsy samples and
eight ESCC cell lines.
RESULTS: MRP2-positive immunostaining was more frequently observed in ESCCs with NACT than in those without NACT (27.3 vs
5.4%). The MRP2-positive patients showed poorer prognosis than MRP2-negative patients (5-year survival rate, 25.6 vs 55.7%).
Concordantly, ESCC with NACT showed 2.1-fold higher mRNA expression of MRP2 than those without NACT (P¼0.0350).
In pre-therapeutic biopsy samples of patients with NACT, non-responders showed 2.9-fold higher mRNA expression of MRP2 than
responders (P¼0.0035). Among the panel of ESCC cell lines, TE14 showed the highest MRP2 mRNA expression along with
the strongest resistance to CDDP. Inhibition of MRP2 expression by small-interfering RNA reduced chemoresistance to CDDP.
CONCLUSION: Our data suggested that MRP2 is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in
advanced ESCC patients.
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Oesophageal squamous cell carcinoma (ESCC) is the major
histological form of oesophageal cancer in East Asian countries.
It is one of the most lethal malignancies of the digestive tract and
in most cases the initial diagnosis is established only once the
malignancy is in the advanced stage (Shimada et al, 2003).
Multimodal therapies are therefore necessary to prolong the
survival of ESCC patients. Chemotherapy has become the standard
first-line therapy for advanced ESCC patients, especially neo-
adjuvant chemotherapy (NACT) (Tamoto et al, 2004). However,
the initial response rate for NACT remains at 35–66% (Ajani et al,
1992; Iizuka et al, 1992; Hilgenberg et al, 1988; Ilson et al, 1998,
1999; Millar et al, 2005) and non-responders risk serious adverse
effects without achieving any survival benefit.
The effectiveness of chemotherapy is often limited by drug-
resistance factors in the tumours themselves. In fact, some
tumours are intrinsically resistant to many kinds of chemo-
therapeutic agents, whereas other tumours, initially sensitive, often
recur or become resistant not only to the initial agents used
but also to those used subsequently. These two types of
chemoresistance, intrinsic and acquired, are clinically serious
problems in many types of cancer including ESCC; however, the
molecular mechanisms underlying this resistance are not fully
understood. More investigation into the mechanisms of chemore-
sistance in ESCC is needed with the goal of identifying novel
predictive markers that can accurately identify non-responders
before the administration of chemotherapy, thus enabling
personalised therapies in ESCC patients.
Several members of the ATP-binding cassette (ABC) transporter
superfamily have an important role in drug resistance in tumour
cell models as well as in the clinic (Lage, 2003). These transporters
mediate the ATP-dependent cellular efflux of chemotherapeutic
drugs. Of the 48 human ABC transporters, multidrug resistance
protein 2 (MRP2; also designated as ABCC2 or cMOAT) is
expressed in the hepatocyte canalicular membrane (Kool et al,
1997), in which it functions as the major exporter of organic
anions from the liver into the bile (Wada et al, 1998). Multidrug
resistance protein 2 is also expressed in the kidney, gall bladder,
small intestine, colon, and lung (Surowiak et al, 2006). Interest-
ingly, several cisplatin (CDDP)-resistant human cancer cell lines
overexpress MRP2, including ovarian cancer, hepatocellular
carcinoma, bladder cancer, and colon cancer (Taniguchi et al,
1996; Kool et al, 1997; Liedert et al, 2003; Materna et al, 2005).
In vitro data also implicated MRP2 in multidrug resistance (MDR)
mechanisms during chemotherapy in some cancer cell lines
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s(Koike et al, 1997; Materna et al, 2006; Ma et al, 2009). However,
few studies have investigated MRP2 expression in ESCC (Gan et al,
2010; Tanaka et al, 2010), and thus the relationship between MRP2
expression and chemoresistance in ESCC remains unclear.
The present study examined the clinical significance of MRP2
expression and its role in intrinsic and acquired resistance to
chemotherapy in ESCC patients.
PATIENTS AND METHODS
Patients and treatments
The present study examined samples from 81 patients with
histopathologically confirmed primary thoracic oesophageal can-
cer who underwent surgical resection at our hospital from 1988
to 2007. Table 1 details the patient characteristics. The cohort
comprised 9 female and 72 male patients, aged from 42 to 80 years
(median 62 years). Sub-total oesophagectomy by right thoracot-
omy with two or three-field lymphadenectomy was performed in
all patients. Curative resection (R0) was achieved in 75 patients
(92.6%), whereas the remaining 6 (7.4%) patients underwent a
non-curative resection (R1, 2). None of the patients died of post-
operative complications. A total of 44 patients (54.3%) with lymph
node metastasis at initial diagnosis received NACT comprising two
courses of 5-fluorouracil (5-FU), CDDP, and doxorubicin (DXR)
(Akita et al, 2006; Yano et al, 2006; Matsuyama et al, 2007; Makino
et al, 2008, 2010). Only a few patients who showed multiple
metastatic lymph nodes in the surgical specimen received a
regimen of docetaxel or CDDP plus 5-FU after operation (Ando
et al, 2003).
After surgery, the patients were surveyed every 3 months by
physical examination and measurement of serum tumour markers,
every 6 months by CT scan and abdominal ultrasonography, and
every year by endoscopy until tumour recurrence was evident.
Patients with tumour recurrence received chemotherapy or
chemoradiotherapy as long as their systemic condition permitted.
The mean overall survival (OS) was 31.6 months and mean disease-
free survival was 28.3 months. The mean follow-up period after
surgery was 42.9 months.
Immunohistochemical analysis
MRP2 protein accumulation was examined by immunohisto-
chemical (IHC) staining of formalin-fixed and paraffin-embedded
ESCC tissue sections (Makino et al, 2009). Briefly, after de-
paraffinization in xylenes and dehydration through graded ethanol
solutions; endogenous peroxidase activity was blocked by incuba-
tion with 3% hydrogen peroxide for 20min. The tissue sections
were then heated at 951C for 40min in citrate buffer (0.05moll
 1,
pH 6.0) for antigen retrieval. The sections were then incubated
with mouse monoclonal antibody to MRP2 (Clone: M2III-6,
ALEXIS Biochemicals, dilution 1:10) for 2h at room temperature,
and antibody binding was visualised using the labeled-streptavidin
biotin method. Negative controls for the IHC included omission of
the primary antibody. Normal human liver tissue was used as a
positive control. MRP2 staining for each ESCC sample was judged
‘positive’ when more than 10% of the cancer cells in the section
were immunoreactive to MRP2, and ‘negative’ when 10% or less of
the cells were positive. All slides were assessed by two observers,
independently and then in conference; both were blinded to the
clinico-pathological parameters.
Quantitative RT–PCR analysis
Total RNA was extracted from fresh frozen resected tumours or
endoscopic biopsy samples from ESCCs patients, and from cancer
cell lines using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).
Complementary DNA (cDNA) was generated from 1mg RNA in a
final volume of 20ml containing oligo-(dT)-15 primer and avian
myeloblastosis virus transcriptase, using the Reverse Transcription
System (Promega, Madison, WI, USA). Analysis by PCR was
performed using a LightCycler, real-time monitoring thermal
cycler. Reaction mixture for PCR was prepared containing 2mlo f
cDNA template, 3mmoll
 1 MgCl2, and 250nmoll
 1 of primer
pairs, using LightCycler FastStart DNA Master SYBR Green I
(Roche Diagnostics, Mannheim, Germany). The amount of each
transcript was normalised against the expression of the house-
keeping gene porphobilinogen deaminase (PBGD). Standard
curves were constructed with 10-fold serial dilutions of cDNA
obtained from non-cancerous oesophageal mucosal cell layers of
tissue samples from 10 cases as a standard mixture. The sequences
of PCR primers for PBGD, MRP2 were as follows: forward primer
50-TGTCTGGTAACGGCAATGCGGCTGCAAC-30, reverse primer
50-TCAATGTTGCCACCACACTGTCCGTCT-30 used for amplifica-
tion of PBGD, forward primer 50-TAATGGTCCTAGACAACGGG-30,
reverse primer 50-GGGCCTTCTGCTAGAATTT-30 for MRP2. The
PCR cycling condition was set as follows: an initial denaturing step
at 951C for 10min and 40 cycles at 951C for 15s, 581C for 10s, and
721C for 25s. The relative amount of cDNA in each sample
was measured by interpolation on the standard curve, and then
the relative ratio of MRP2/PBGD mRNA expression in log2 scale
was calculated for each ESCC sample.
Knockdown analysis using MRP2-siRNAs
Two small-interfering RNA (siRNA-1, -2) of MRP2 (HSS102057,
HSS174719) and negative control (NC) (Medium GC duplex of
stealth RNAi NC duplexes) were purchased from Invitrogen.
Table 1 Correlation between MRP2 expression by immunohisto-
chemistry and various clinico-pathological parameters
MRP2 expression
Parameter Positive Negative Total P-value
Age (years)
o65 8 (16.3) 41 (83.7) 49 0.7731
X65 6 (18.8) 26 (81.2) 32
Gender
Male 10 (13.9) 62 (86.1) 72 0.0435
Female 4 (44.4) 5 (55.6) 9
Histopathology
Well-, moderately differentiated 10 (16.7) 50 (83.3) 60 0.7500
Poorly differentiated 4 (19.0) 17 (81.0) 21
Location
Upper, middle thoracic oesophagus 6 (11.5) 46 (88.5) 52 0.1227
Lower thoracic oesophagus 8 (27.6) 21 (72.4) 29
Neo-adjuvant chemotherapy
Yes 12 (27.3) 32 (72.7) 44 0.0161
No 2 (5.4) 35 (94.6) 37
pT
T0–2 4 (16.7) 20 (83.3) 24 40.9999
T3–4 10 (17.5) 47 (82.5) 57
Number of pN
o4 6 (11.1) 48 (88.9) 54 0.0594
X4 8 (29.6) 19 (70.4) 27
pStage
Stages 0–2 4 (12.1) 29 (87.9) 33 0.3800
Stages 3–4 10 (20.8) 38 (79.2) 48
pT, pN, pStage (pathological classification) according to TNM classification.
MRP2 and chemoresistance in oesophageal cancer
M Yamasaki et al
708
British Journal of Cancer (2011) 104(4), 707–713 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sAmong the eight ESCC cell lines supplied by RIKEN cell bank
(Tsukuba, Japan), TE14 cells showed the highest MRP2 mRNA
expression and were subsequently transfected with 15nmoll
 1
siRNA using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM I
Reduced Serum Medium (Invitrogen). After 24h, the medium was
replaced by standard medium, and then 96h from the siRNA
administration, cells were collected for the following growth
inhibitory assay as described below.
Growth inhibitory assay
Cells (TE14, 1 10
4 cells per well) were added in triplicate to a
96-well microplate, and after overnight incubation, the medium
was replaced with 100ml of fresh medium containing various
concentrations of DXR and CDDP, both of which chemoagents
have been reported to be transported by MRP2 in some types of
cell lines. The TE14 cells suspended in complete medium were
used as a control for cell viability. After 4h (DXR and CDDP)
treatment, the cells were washed with fresh medium. The number
of viable cells was assessed by the 3-(4-, 5-dimethylthiazol-2-yl)-2,
5-dyphenyl tetrazolium bromide (MTT) (Sigma, St Louis, MO,
USA) assay. Briefly, 10ml (50mg) of MTT were added to each
well after 48h (DXR and CDDP) from the chemoadministration.
The plate was incubated for 4h at 371C, followed by removal
of medium and the addition of 100ml of 2-propanol to each well to
dissolve the resultant formazan crystals. Plate absorbance was
measured in a microplate reader at a wavelength of 650nm. After a
pulsed exposure, the IC50 was calculated as percentage of control
cultures that were not exposed to chemoagents using an
interpolated logarithmic concentration curve. Results were derived
from three independent sets of triplicate experiments.
Statistical analysis
Data are expressed as mean±s.d. Correlations between MRP2
expression and various clinico-pathological parameters were
each evaluated by the w
2 test and Fisher’s exact probability test.
Differences in continuous parameters between two groups were
evaluated by the Mann–Whitney’s U-test. Prognostic variables
were assessed by log-lank test, and OS was analysed by Kaplan–
Meier method. These analyses were carried out using SPSS
for Windows v10 (SPSS, Chicago, IL, USA). A P-value of less than
0.05 denoted the presence of statistical significance.
RESULTS
MRP2 protein expression by immunohistochemistry in
ESCC and its correlation with clinico-pathological
parameters
A total of 81 samples that contained both cancerous and
non-cancerous lesions were evaluated for MRP2 protein expres-
sion by IHC analysis. As a positive control, liver tissue showed
strong MRP2 immunostaining mainly in the hepatocyte plasma
membrane (Figure 1A). No normal squamous epithelium showed
significant levels of immunostaining (Figure 1B). Of all samples,
14 (17.3%) showed positive MRP2 expression, mainly in the cell
membrane and cytoplasm of tumour cells (Figure 1C), whereas the
remaining 67 (82.7%) were negative for MRP2 expression
(Figure 1D). The positive staining was almost homogeneous in
single-cancer nests and among different areas (surface, central,
and deepest areas) of the cancer lesion.
Table 1 lists the correlations between MRP2 expression and
various clinico-pathological parameters. Of note, MRP2 expression
was exceptional in the ESCC patients without NACT (2 out of 37,
5.4%), but was significantly more frequent in patients after NACT
(12 out of 44, 27.3%). Women tended to have a higher rate of
MRP2 expression than men (44.4 vs 13.9%, respectively), although
the difference was small. Other clinico-pathological parameters
including age, histological type, tumour location, pT, pN, and
pStage were not associated with MRP2 expression.
Disease recurrence after curative resection was diagnosed in 35
(46.7%) of 75 patients with curative resection (R0) and the mean
Figure 1 MRP2 expression by immunohistochemistry. (A) Strong MRP2 expression in liver tissue as a positive control (magnification,  400).
(B) Representative normal squamous epithelium negative for MRP2 expression (magnification,  200). (C) Representative MRP2-positive ESCC showing
staining mainly in the membrane and cytoplasm of tumour cells (magnification,  200). (D) Representative MRP2-negative oesophageal squamous cell
carcinoma with no appreciable staining of tumour cells (magnification,  200).
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stime to recurrence was 10.5 months. A total of 35 (43.2%) patients
died and their average survival time from diagnosis to death was 1.4
years (range 0.2–4.2 years). The total 5-year OS rate was 50.9% and
MRP2-positive patients showed a significantly poorer prognosis than
MRP2-negative patients (5-year OS 55.7 vs 25.6%) (Figure 2).
MRP2 mRNA expressions in resected specimens and
endoscopy biopsy samples
RT–PCR analysis was performed to quantify the expression of
MRP2 mRNA in surgically removed specimens from 26 represen-
tative cases, including 16 with NACT and 10 without NACT. MRP2
mRNA expression in tumours with NACT was 2.1-fold higher than
in those without NACT, although there was no significant
difference in TNM stage and other clinico-pathological parameters
between the groups (data not shown) (Figure 3A).
The association between MRP2 mRNA expression and the effect
of NACT was investigated in biopsy samples before NACT from 42
patients; the response of these patients to NACT was classified as
non-responder in 22 and responder in 20. As shown in Figure 3B,
MRP2 mRNA expression in non-responders was 2.9-fold higher
than that in responders. Again, although these 42 samples were all
advanced tumours with clinically positive lymph node metastases,
there was no significant difference in clinical background
parameters between the groups (data not shown).
Association between MRP2 mRNA expression and
chemoresistance in ESCC cancer lines
To explore whether MRP2 expression functions specifically in
chemoresistance to CDDP, we tested for a correlation between
MRP2 mRNA expression and CDDP resistance (IC50) in eight
ESCC cell lines (Figure 4). Relatively high MRP2 expression was
observed in TE14 and TE5 cell lines, both of which displayed
strong resistance to CDDP. Regression analysis showed a
significant correlation between MRP2 mRNA expression and IC50
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Figure 2 Survival curves according to MRP2 expression. Overall survival
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by Kaplan–Meier method. Differences between two groups were
evaluated by log–rank test. Ordinate: overall survival rate, abscissa: time
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between responders and non-responders at biopsy (B). (A) The relative ratio of MRP2 mRNA expression in resected tumours treated with neo-adjuvant
chemotherapy (n¼16) was significantly higher than in untreated cancers (n¼10). (B) In endoscopy biopsy samples, the relative ratios of MRP2 mRNA
expression in responders (n¼22) were significantly higher than those in non-responders (n¼20). Data are shown as mean±s.d. (log2 values).
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resistance (IC50) in eight cell lines of ESCC. Relatively high MRP2
expression was observed in TE14 and TE5 cell lines, both of which
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sagainst CDDP (R¼0.741, R2¼0.549), suggesting that ESCC cell
lines with higher MRP2 mRNA expression were more resistant
to CDDP compared with those showing lower MRP2 expression.
To confirm these findings by an alternative approach, we
transfected MPR2 siRNAs into the TE14 line, which had the
highest cellular MRP2 expression. The specific gene silencing
started 48h after the administration of siRNA (two siRNAs for
MRP2 with different sequences were used: siRNA-1 and siRNA-2)
and continued for 144h, which was examined by quantitative PCR,
resulting in 63.8% (siRNA-1) and 65.9% (siRNA-2) of peak MRP2
downregulation compared with NCs. The knockdown effect was
stable during this period. As shown in Table 2, downregulation of
MRP2 conferred increased sensitivity to CDDP, but not to DXR.
IC50 values against CDDP were significantly lower in TE14 cell
lines transfected with siRNA-1 and siRNA-2 compared with those
transfected with NC (20.5±1.4, 17.8±1.2 vs 32.4±1.2mM, (siRNA-
1 vs NC); P¼0.0003, (siRNA-2 vs NC); P¼0.0005). On the other
hand, IC50 values of DXR were almost similar among TE14 cells
transfected with siRNA-1, siRNA-2, and NC (5.8±0.47, 5.4±0.54
vs 6.2±0.16mM, (siRNA-1 vs NC); P¼0.2869, (siRNA-2 vs NC);
P¼0.2285).
DISCUSSION
To our knowledge, this study is the first to identify the clinical
significance of MRP2 expression in chemoresistance in ESCC. Such
a relationship was strongly suggested by the findings that
(1) MRP2 expression in the clinical biopsy samples before NACT
was significantly negatively correlated with the effect of NACT, and
(2) in the cultured cell line, artificial MRP2 downregulation
resulted in increased resistance to the chemotherapy. Furthermore,
the clinical samples of patients treated with NACT showed
significantly higher expression of MRP2 at both the protein and
mRNA levels than those without NACT, and the increased MRP2
expression was associated with poor prognosis. Although compli-
cated, these clinical observations implicated MRP2 in the acquired
resistance to chemotherapy commonly encountered in ESCC
patients.
Intrinsic or acquired drug resistance is a major factor limiting
the effectiveness of chemotherapy in various cancers including
ESCC. Drug resistance by tumours occurs not only to a single
cytotoxic agent but also in the form of cross-resistance to many
agents called MDR. One of the major mechanisms of MDR is an
increased ability of tumour cells to actively efflux drugs,
decreasing the intracellular drug accumulation. This mechanism
is mediated by ATP-dependent drug efflux pumps known as ABC
transporters (Leonard et al, 2003; Ozben, 2006). To date, at least
48 human ABC transporters have been identified, and they have
been divided into seven sub-families, ABC-A through ABC-G. The
first ABC transporter identified in this context was P-glycoprotein
(PgP, MDR1, ABCB1) (Kartner et al, 1983), and in the absence of
overexpressed MDR1, the protein MRP1, ABCC1 was discovered
because of the MDR phenotype (Cole et al, 1992).
Cisplatin resistance is not a feature of MDR phenotypes
conferred by either MDR1 or MRP1 (Borst et al, 2000). The
finding that ABC transporter MRP2 could mediate active efflux of
CDDP conjugated to glutathione (Taniguchi et al, 1996), supported
by evidence that intracellular glutathione levels were related to
CDDP toxicity (Ozols, 1985), suggested a possible role for active
efflux as a resistance mechanism. In addition, human carcinoma
cell line studies showed increased levels of MRP2 mRNA
associated with relative CDDP resistance, decreased intracellular
accumulation of CDDP, and decreased DNA adduct formation
(Kool et al, 1997; Liedert et al, 2003). In ESCC cell lines (TE2,
TE13) Tanaka et al (2010), in their analysis of the intracellular
localisation of CDDP by using in-air micro-particle induced X-ray
emission, recently reported that TE2 cells, which express lower
MRP2 than TE13, had higher intracellular CDDP concentrations
and sensitivity than TE13 cells. This is also in agreement with our
present in vitro data regarding CDDP. In human tissue samples,
accumulating evidence indicates that MRP2 expression is also
associated with intrinsic CDDP resistance in the clinical setting,
using tissues obtained from patients with colorectal cancer
(Hinoshita et al, 2000), small-cell lung carcinoma (Ushijima
et al, 2007), and ovarian cancer (Surowiak et al, 2006). These
results are also consistent with our data from cancer tissue
samples, although our in vitro data involving each single agent
could not necessarily be translated directly to a clinical response to
combination chemotherapy because of possible synergistic effects.
However, in contrast with these data, other studies failed to show a
significant association between MRP2 expression and chemosen-
sitivity in patients with ovarian cancer (Arts et al, 1999; Materna
et al, 2004) or lung cancer (Filipits et al, 2007; Kim et al, 2009).
It therefore seems likely that multiple factors such as drug
accumulation, DNA repair capacity, and apoptotic sensitivity
contribute to clinical tumour chemosensitivity, and a mechanistic
relationship could be difficult to detect amongst an unselected
patient cohort in which a number of other factors also affect
clinical outcome. As clinical significance of MRP2 other than
chemosensitivity, Gan et al (2010) reported that MRP2 expression
was significantly higher in poorly differentiated ESCC tumours
compared with moderate or well differentiated ones, which was not
observed in our study.
In terms of the contribution to acquired chemoresistance, the
present IHC and qRT–PCR data showed higher MRP2 expression
in resected tumours with NACT compared with those without
NACT, implying residual tumours after NACT acquired the feature
of chemoresistance. Unfortunately, we could not compare MRP2
expression levels in cancer tissues from the same patient before
and after NACT because no samples were available. Nooter et al
(1998) reported significantly higher MRP expression, although not
specific MRP2 expression, in ESCC tumours from non-responders
to CDDP-based chemotherapy when comparing MRP levels in
paired tumour samples before and after chemotherapy, suggesting
that chemotherapy was selected for drug-resistant cell clones.
Furthermore, other in vitro analyses by Noma et al (2008)
established two CDDP-resistant pancreatic cancer cell lines
(SUIT-2-CD3 and SUIT-2-CD4) by continuously administering
10nM CDDP for 3 and 4 months, respectively. Results of RT–PCR
indicated that induction of MRP2 mRNA expression was
significantly increased by 1.5- and 2.5-fold in SUIT-2-CD3 and
SUIT-2-CD4 cells, respectively, compared with parent cells,
whereas MRP1 and MRP3 expression remained unchanged,
implying a contribution of MRP2 to acquired resistance for CDDP
in pancreatic cancer.
An important observation regarding the functional significance
of MRP2 expressed in tumour cells could be the sub-cellular
localisation. In normal tissues, MRP2 is expressed in functionally
Table 2 Modulation of resistance against cisplatin and doxorubicin
by MRP2 siRNA
IC50
Cisplatin (lM) Doxorubicin (lM)
TE14 NC 32.4 (±1.2) 6.2 (±0.16)
TE14 siRNA-1 20.5 (±1.4)
a 5.8 (±0.47)
b
TE14 siRNA-2 17.8 (±1.2)
c 5.4 (±0.54)
d
Abbreviations: NC¼negative control; IC50¼half maximal inhibitory concentration;
siRNA¼small-interfering RNA.
aP¼0.0003, compared with NC.
bP¼0.2869,
compared with NC.
cP¼0.0005, compared with NC.
dP¼0.2285, compared with
NC. Data are shown as mean±s.d.
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spolarised cells in which it specifically localises to the apical
membrane of these cells. Apical localisation has also been
described in tumours arising from these sites, a feature attributed
to a targeting signal in the C-terminus of the MRP2 molecule
(Harris et al, 2001). Single-nucleotide polymorphisms in MRP2
have been described that result in cytoplasmic localisation of the
protein and that may reduce in vivo function (Hirouchi et al,
2004). Reduced CDDP sensitivity has also been reported in
polarised mammalian kidney cells transfected with appropriately
localised MRP2 (Cui et al, 1999). Furthermore, data of Surowiak
et al (2006) indicated that MRP2 could confer resistance to CDDP
in ovarian carcinoma only when expressed at the nuclear
membrane, and this was supported by in vitro data (Materna
et al, 2006). Although our IHC results showed MRP2-positive
staining of both cytoplasm and membrane in tumour cells, MRP2
protein located in the cell cytoplasm might not function as an
efflux pump (Evers et al, 1998). Further analysis focusing on the
sub-cellular localisation of MRP2, and on the functional and
clinical significance of such cellular location, is needed to elucidate
the specific mechanism of chemoresistance induced by MRP2 in
ESCC.
In conclusion, MRP2 expression seems to be associated with
intrinsic resistance to chemotherapy in patients with ESCC, and is
likely to also have a role in acquired chemoresistance. Further
studies with larger cohorts are warranted to verify these results
prospectively. The findings of this study open the door for
exploration of efficacious treatment strategies and development of
new therapeutic approaches for ESCC.
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